- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04050020
Platelet-rich Plasma (PRP) Injection for Treatment of Erectile Function
October 19, 2020 updated by: Dimitrios Hatzichristou, Institute for the Study of Urological Diseases, Greece
The Effect of Platelet-rich Plasma(PRP) Injection Treatment on Erectile Function: a Double-blind, Placebo Controlled Randomized Clinical Trial
The primary objective of the present study is to investigate and compare the treatment efficacy of PRP injection vs placebo treatment in men with mild-moderate vasculogenic ED, as measured by IIEF.The secondary objective of the present clinical trial is to study the adverse events and safety of the PRP injection treatment in vasculogenic ED patients
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
60
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Thessaloniki, Greece, 54621
- G.Gennimatas Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
40 years to 70 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Consent to participate.
- Age 40-70 years.
- Sexually active in a stable, heterosexual relationship of more than three months duration.
- Presence of Erectile Dysfunction for at least 6 months.
- IIEF-ED: 11-25 at visit 1
- PDE5i users and report some/good response to PDE5i at the last month before screening.
- Agree to suspend all ED therapy for the duration of the study.
- Agree to attempt sexual intercourse at least 4 times every 4 weeks, for the duration of the study without being under the influence of alcohol or recreational drugs. Agree to document the outcome using the Sexual Encounter Profile (SEP) diary, as needed.
Exclusion Criteria:
- Previous major pelvic surgery or pelvic trauma that could impact erectile function, such as radical prostatectomy, radical cystectomy, rectal surgery. Patients with previous TURP surgery without sequelae of iatrogenic ED, may be included.
- Previous penile surgery of any kind except circumcision and condyloma removal, such as penile lengthening, penile cancer surgery, penile plication, grafting.
- Previous history of priapism or penile fracture
- Previous radiation therapy to pelvis.
- Abnormal morning serum testosterone level defined as a value lower than 300 ng/dL +/- 5 %(indicative of untreated hypogonadism), or greater than 1197 ng/dL +/- 5%.
- Current or previous hormone usage, other than prescribed testosterone, clomiphene or thyroid medication. Subjects with prior or current use of hormonal treatment for prostate cancer are also excluded.
- Psychogenic ED.
- Peyronie's Disease or penile curvature that negatively influences sexual activity.
- Anatomical or neurological abnormalities in the treatment area.
- Any untreated medical condition (medical history)
- Patients with generalized polyneuropathy, or neurological conditions irrespective of cause, such as severe diabetes, multiple sclerosis or Parkinson's Disease.
- Refusal to suspend ED therapy for duration of study. Subjects who are using Tadalafil as a treatment for BPH (Benign Prostatic Hyperplasia) will also be excluded.
- Men deemed not healthy enough to participate in sexual activity.
- Any condition or behavior that indicates to the Principal Investigator that the subject is unlikely to be compliant with study procedures and visits.
- Any health history or laboratory result that indicates to the Principal Investigator that the subject has a significant medical condition and should not participate in the study.
- History of consistent treatment failure with PDE5 inhibitors for therapy of ED.
- Any history of significant psychiatric disease, such as bipolar disorder or psychosis, greater than one lifetime episode of major depression, current depression of moderate or greater severity. Patients who are currently using SSRI or psychotropic medications.
- Partners who are < 18 years of age, who are nursing, who are known to be pregnant at screening, who wish to become pregnant during the study period, who have any gynecologic problems, sexual dysfunction, or major medical conditions that would limit participation in sexual intercourse.
- Patients with any hematological disorder.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Group B
|
All subjects of this group will receive 2 sessions of normal saline penile injection with 30 +/- 3 day treatment interval for all subjects, 10 ml of normal saline will be injected at each session.
|
Active Comparator: Group A
|
All subjects of this group will receive 2 sessions of PRP penile injection with 30 +/- 3 day treatment interval, 10 ml of PRP will be injected at each session.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The % of patients in each group who attain Minimal Clinically Important Difference (MCID) in International Index of Erectile Function -Erectile Function (IIEF-EF) domain from baseline to 24 weeks after final treatment.
Time Frame: at 24 weeks follow up visit
|
MCID is defined according to baseline ED severity as:Improvement by 5 or more in the EF domain score of the IIEF for patients with moderate ED at baseline and by 2 or more in the EF domain score of the IIEF for patients with moderate ED at baseline
|
at 24 weeks follow up visit
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The % of patients in each group who attain MCID in IIEF-EF domain from baseline to 12 weeks after final treatment.
Time Frame: at 12 weeks follow up visit
|
MCID is defined according to baseline ED severity as:Improvement by 5 or more in the EF domain score of the IIEF for patients with moderate ED at baseline and by 2 or more in the EF domain score of the IIEF for patients with moderate ED at baseline
|
at 12 weeks follow up visit
|
The % of patients in each group who attain MCID in IIEF-EF domain from baseline to 4 weeks after final treatment.
Time Frame: at 4 weeks follow up visit
|
MCID is defined according to baseline ED severity as:Improvement by 5 or more in the EF domain score of the IIEF for patients with moderate ED at baseline and by 2 or more in the EF domain score of the IIEF for patients with moderate ED at baseline
|
at 4 weeks follow up visit
|
The difference between the PRP group (2 sessions of PRP) and the placebo group in the change of the IIEF-ED score from baseline to 4 weeks after final treatment.
Time Frame: baseline and 4 weeks follow up visit
|
EF domain of the IIEF questionnaire will be completed.
IIEF-EF consists of items 1,2,3,4,5,15 of the IIEF questionnaire.According to the score of the iIEF-EF there are five categories of erectile function: 1-10 (Severe Erectile Dysfunction), 11-16(Moderate dysfunction), 17-21(Mild to moderate dysfunction), 22-25(Mild dysfunction), 26-30 (No dysfunction).
|
baseline and 4 weeks follow up visit
|
The difference between the PRP group (2 sessions of PRP) and the placebo group in the change of the IIEF-ED score from baseline to 12 weeks after final treatment.
Time Frame: baseline and 12 weeks follow up visit
|
EF domain of the IIEF questionnaire will be completed.IIEF-EF consists of items 1,2,3,4,5,15 of the IIEF questionnaire.According to the score of the iIEF-EF there are five categories of erectile function: 1-10 (Severe Erectile Dysfunction), 11-16(Moderate dysfunction), 17-21(Mild to moderate dysfunction), 22-25(Mild dysfunction), 26-30 (No dysfunction)
|
baseline and 12 weeks follow up visit
|
The difference between the PRP group (2 sessions of PRP) and the placebo group in the change of the IIEF-ED score from baseline to 24 weeks after final treatment.
Time Frame: baseline and 24 weeks follow up visit
|
EF domain of the IIEF questionnaire will be completed.IIEF-EF consists of items 1,2,3,4,5,15 of the IIEF questionnaire.According to the score of the iIEF-EF there are five categories of erectile function: 1-10 (Severe Erectile Dysfunction), 11-16(Moderate dysfunction), 17-21(Mild to moderate dysfunction), 22-25(Mild dysfunction), 26-30 (No dysfunction)
|
baseline and 24 weeks follow up visit
|
The difference between the PRP group (2 sessions of PRP) and the placebo group in the change in Sexual Encounter Profile Question 3 (SEP3) score from baseline to 4 weeks after final treatment.
Time Frame: baseline and 4 weeks follow up visit
|
The percent of subjects who answer ''YES'' in question 3 of SEP questionnaire will be reported
|
baseline and 4 weeks follow up visit
|
The difference between the PRP group (2 sessions of PRP) and the placebo group in the change in Sexual Encounter Profile Question 3 (SEP3) score from baseline to 12 weeks after final treatment.
Time Frame: baseline and 12 weeks follow up visit
|
The percent of subjects who answer ''YES'' in question 3 of SEP questionnaire will be reported
|
baseline and 12 weeks follow up visit
|
The difference between the PRP group (2 sessions of PRP) and the placebo group in the change in Sexual Encounter Profile Question 3 (SEP3) score from baseline to 24 weeks after final treatment.
Time Frame: baseline and 24 weeks follow up visit
|
The percent of subjects who answer ''YES'' in question 3 of SEP questionnaire will be reported
|
baseline and 24 weeks follow up visit
|
The difference between the PRP group (2 sessions of PRP) and the placebo group in Erectile Dysfunction Inventory of Treatment Satisfaction (EDITS) questionnaire score
Time Frame: 4,12, 24 weeks follow up visit
|
EDITS is an 11-item validated questionnaire assessing treatment satisfaction.
The 11 items in the EDITS questionnaire are combined into an index score by computing the mean of the 11 item scores and multiplying this value by 25.
This results in an EDITS index score with a range of 0 (extremely low treatment satisfaction) to 100 (extremely high treatment satisfaction) for an individual patient.
|
4,12, 24 weeks follow up visit
|
The difference between the PRP group (2 sessions of PRP) and the placebo group in the the Pain Visual Analogue Scale (VAS) after each injection treatment session
Time Frame: at week 0 and 4
|
It will be assessed by the pain VAS, right after each LIST session.
Pain VAS is a unidimensional measure of pain intensity .
It is a continuous scale comprised of a horizontal (HVAS) or vertical (VVAS) line, usually 10 centimeters (100 mm) in length, anchored by 2 verbal descriptors, one for each symptom extreme.
For pain intensity, the scale is most commonly anchored by "no pain" (score of 0) and "pain as bad as it could be" or "worst imaginable pain" (score of 100 [100-mm scale].
To avoid clustering of scores around a preferred numeric value, numbers or verbal descriptors at intermediate points are not recommended.
The following cut points on the pain VAS have been recommended: no pain (0-4 mm), mild pain (5-44 mm), moderate pain (45-74 mm), and severe pain (75- 100 mm
|
at week 0 and 4
|
Number of patients with treatment related adverse events
Time Frame: 28 weeks
|
Potential treatment related adverse events after the first PRP injection session and during the 3 month follow up period will be reported
|
28 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Dimitrios Hatzichristou, Prof., G.Gennimatas General Hospital, Thessaloniki,Greece
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Epifanova MV, Gvasalia BR, Durashov MA, Artemenko SA. Platelet-Rich Plasma Therapy for Male Sexual Dysfunction: Myth or Reality? Sex Med Rev. 2020 Jan;8(1):106-113. doi: 10.1016/j.sxmr.2019.02.002. Epub 2019 Mar 19.
- Scott S, Roberts M, Chung E. Platelet-Rich Plasma and Treatment of Erectile Dysfunction: Critical Review of Literature and Global Trends in Platelet-Rich Plasma Clinics. Sex Med Rev. 2019 Apr;7(2):306-312. doi: 10.1016/j.sxmr.2018.12.006. Epub 2019 Mar 2.
- Wu YN, Wu CC, Sheu MT, Chen KC, Ho HO, Chiang HS. Optimization of platelet-rich plasma and its effects on the recovery of erectile function after bilateral cavernous nerve injury in a rat model. J Tissue Eng Regen Med. 2016 Oct;10(10):E294-E304. doi: 10.1002/term.1806. Epub 2013 Aug 16.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
September 2, 2019
Primary Completion (Actual)
March 26, 2020
Study Completion (Actual)
September 24, 2020
Study Registration Dates
First Submitted
August 6, 2019
First Submitted That Met QC Criteria
August 6, 2019
First Posted (Actual)
August 8, 2019
Study Record Updates
Last Update Posted (Actual)
October 20, 2020
Last Update Submitted That Met QC Criteria
October 19, 2020
Last Verified
October 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 65-08/10/18
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Erectile Dysfunction Due to Arterial Insufficiency
-
University of VirginiaActive, not recruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Erectile Dysfunction Due to General Medical Condition | Erectile Dysfunction Due to Arterial InsufficiencyUnited States
-
Cairo UniversityRecruitingErectile Dysfunction | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Simple Prostatectomy | Erectile Dysfunction With Diabetes Mellitus | Erectile Dysfunction Due to Arterial Disease | Erectile Dysfunction Due to Injury | Erectile Dysfunction Due to Neuropathy and other conditionsEgypt
-
Ankara Yildirim Beyazıt UniversityCompletedErectile Dysfunction | Erectile Dysfunction Due to Arterial Disease | Erectile Dysfunction Due to Venous Disorder
-
The Cleveland ClinicRecruitingErectile Dysfunction | Chronic Prostatitis | Chronic Pelvic Pain Syndrome | Erectile Dysfunction Following Radical Prostatectomy | Erectile Dysfunction Following Radiation Therapy | Erectile Dysfunction Due to Arterial Insufficiency | Erectile Dysfunction Due to Arterial DiseaseUnited States
-
Medtronic EndovascularMedtronicTerminatedErectile Dysfunction Due to Arterial InsufficiencyUnited States
-
Bursa City HospitalCompletedErectile Dysfunction Due to Arterial DiseaseTurkey
-
University of Roma La SapienzaUniversity of PisaCompletedErectile Dysfunction Due to Arterial DiseaseItaly
-
Kasr El Aini HospitalNot yet recruitingErectile Dysfunction | Erectile Dysfunction Due to Venous DisorderEgypt
-
The University of The West IndiesCompletedPlatelet Dysfunction Due to DrugsTrinidad and Tobago
-
The University of The West IndiesRecruiting
Clinical Trials on Platelet-Rich Plasma (PRP)
-
VivaTech International, Inc.RecruitingOsteoarthritisUnited States
-
Stanford UniversityPartnership for Clean CompetitionCompletedRheumatic Diseases | TendinopathyUnited States
-
Damascus UniversityCompletedBone ResorptionSyrian Arab Republic
-
Sutherland Medical CenterActive, not recruitingRotator Cuff Tears | Rotator Cuff TendinosisPoland
-
University of Colorado, DenverTerumo BCTCompletedOsteochondritis DissecansUnited States
-
Germans Trias i Pujol HospitalCompletedEvaluation of the Efficacy of Platelet-rich Plasma (PRP) on Advanced Endoscopic Resection TechniquesEndoscopic Submucosal Dissection | Platelet-rich Plasma | Endoscopic Mucosal ResectionSpain
-
University of Kansas Medical CenterUnknownTympanic Membrane PerforationUnited States
-
Cairo UniversityFayoum UniversityTerminated
-
Damascus UniversityCompletedPeriorbital HyperpigmentationSyrian Arab Republic
-
Buddhist Tzu Chi General HospitalUnknownInterstitial CystitisTaiwan